Literature DB >> 24018407

Dual RAS blockade-unresolved controversy?

Harikrishna Makani1, Franz H Messerli, Sripal Bangalore, Kavit A Desouza, Arpit Shah, Johannes F E Mann.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24018407     DOI： 10.1038/nrneph.2013.82-c1

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  14 in total

1.  Renin-angiotensin system: Meta-analyses can misdirect decisions on treatment.

Authors:  Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2013-04-30       Impact factor: 28.314

2.  Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial.

Authors:  Johannes F E Mann; Craig Anderson; Peggy Gao; Hertzel C Gerstein; Michael Boehm; Lars Rydén; Peter Sleight; Koon K Teo; Salim Yusuf
Journal:  J Hypertens       Date:  2013-02       Impact factor: 4.844

3.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

Authors:  David N Juurlink; Muhammad M Mamdani; Douglas S Lee; Alexander Kopp; Peter C Austin; Andreas Laupacis; Donald A Redelmeier
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

4.  Role of remission clinics in the longitudinal treatment of CKD.

Authors:  Piero Ruggenenti; Elena Perticucci; Paolo Cravedi; Vincenzo Gambara; Marco Costantini; Sanjib Kumar Sharma; Annalisa Perna; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2008-03-19       Impact factor: 10.121

5.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

Authors:  Johannes F E Mann; Roland E Schmieder; Matthew McQueen; Leanne Dyal; Helmut Schumacher; Janice Pogue; Xingyu Wang; Aldo Maggioni; Andrzej Budaj; Suphachai Chaithiraphan; Kenneth Dickstein; Matyas Keltai; Kaj Metsärinne; Ali Oto; Alexander Parkhomenko; Leopoldo S Piegas; Tage L Svendsen; Koon K Teo; Salim Yusuf
Journal:  Lancet       Date:  2008-08-16       Impact factor: 79.321

6.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Authors:  Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Frederik Persson; Akshay S Desai; Maria Nicolaides; Alexia Richard; Zhihua Xiang; Patrick Brunel; Marc A Pfeffer
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

7.  Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

Authors:  Linda F Fried; William Duckworth; Jane Hongyuan Zhang; Theresa O'Connor; Mary Brophy; Nicholas Emanuele; Grant D Huang; Peter A McCullough; Paul M Palevsky; Stephen Seliger; Stuart R Warren; Peter Peduzzi
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-31       Impact factor: 8.237

8.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

Review 9.  Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.

Authors:  Juan P Casas; Weiliang Chua; Stavros Loukogeorgakis; Patrick Vallance; Liam Smeeth; Aroon D Hingorani; Raymond J MacAllister
Journal:  Lancet       Date:  2005-12-10       Impact factor: 79.321

10.  Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.

Authors:  E Imai; J C N Chan; S Ito; T Yamasaki; F Kobayashi; M Haneda; H Makino
Journal:  Diabetologia       Date:  2011-10-13       Impact factor: 10.122
View more
  1 in total

1.  Dual RAS blockade-controversy resolved.

Authors:  Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2013-09-10       Impact factor: 28.314
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.